ZIM
LYEL icon

Zacks Investment Management’s Lyell Immunopharma LYEL Stock Holding History

Zacks Investment Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-706
Closed -$31.5K – 683
2024
Q1 		$31.5K Buy
+706
New +$30.2K ﹤0.01% 628
2023
Q2 		– Sell
-542
Closed -$25.6K – 691
2023
Q1 		$25.6K Hold
542
– – ﹤0.01% 620
2022
Q4 		$37.6K Buy
+542
New +$53.8K ﹤0.01% 588

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zacks Investment Management's LYEL Position: Q2 2024 in Review

Zacks Investment Management sold out of Lyell Immunopharma (LYEL) in Q2 2024, closing a stake of 706 shares — an estimated $31.5K sold.

Zacks Investment Management first reported a position in LYEL in Q4 2022 and held it in 3 quarters. The position peaked at $37.6K in Q4 2022. 119 funds tracked by Wall St. Rank hold LYEL as of Q2 2024.

  • Zacks Investment Management reported no remaining Lyell Immunopharma position as of Q2 2024 after selling out during the quarter.
  • Zacks Investment Management sold 706 Lyell Immunopharma shares in Q2 2024, an estimated $31.5K.
  • Zacks Investment Management first reported a position in Lyell Immunopharma in Q4 2022 and held it in 3 quarters.
  • Zacks Investment Management's Lyell Immunopharma position peaked at $37.6K in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2024.

Based on Zacks Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.